908 Devices (NASDAQ:MASS – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for 908 Devices and Lucid Diagnostics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 908 Devices | 1 | 0 | 1 | 0 | 2.00 |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
908 Devices presently has a consensus target price of $12.00, suggesting a potential upside of 39.05%. Lucid Diagnostics has a consensus target price of $4.13, suggesting a potential upside of 300.49%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than 908 Devices.
Risk & Volatility
Profitability
This table compares 908 Devices and Lucid Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 908 Devices | -62.40% | -14.03% | -10.40% |
| Lucid Diagnostics | -876.72% | N/A | -116.26% |
Earnings and Valuation
This table compares 908 Devices and Lucid Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 908 Devices | $56.20 million | 5.81 | $19.49 million | ($1.00) | -8.63 |
| Lucid Diagnostics | $4.71 million | 44.41 | -$58.01 million | ($0.47) | -2.19 |
908 Devices has higher revenue and earnings than Lucid Diagnostics. 908 Devices is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Lucid Diagnostics beats 908 Devices on 8 of the 14 factors compared between the two stocks.
About 908 Devices
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.
